CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-08 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −360 | $34.90 | $13K | 286,516 |
| 2026-03-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −7,161 | $28.04 | $201K | 162,753 |
| 2026-03-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −2,839 | $28.55 | $81K | 159,914 |
| 2026-03-25 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −10,115 | $29.99 | $303K | 286,876 |
| 2026-03-05 | Gault Cheryl Chief Operating Officer | Sale | −2,014 | $28.93 | $58K | 169,914 |
| 2026-02-19 | Bredt David Chief Scientific Officer | Option exercise 10b5-1 | +6,000 | $1.80 | $11K | 393,075 |
| 2026-02-19 | Bredt David Chief Scientific Officer | Option exercise · Stock Options (Right to Buy) 10b5-1 | −6,000 | 88,080 | ||
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −3,552 | $29.05 | $103K | 558,528 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,281 | $29.80 | $68K | 556,247 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,983 | $29.04 | $87K | 22,829 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,100 | $29.80 | $63K | 20,729 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −900 | $28.02 | $25K | 394,675 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,400 | $28.95 | $156K | 389,275 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −2,200 | $29.59 | $65K | 387,075 |
| 2026-02-02 | Sevigny Jeffrey Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2026-02-02 | Ceesay Abraham Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +428,000 | 428,000 | ||
| 2026-02-02 | Ignelzi Troy A. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +148,000 | 148,000 | ||
| 2026-02-02 | Yeleswaram Krishnaswamy Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2026-02-02 | Bredt David Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +103,000 | 103,000 | ||
| 2026-02-02 | Gault Cheryl Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +132,000 | 132,000 |
Page 4 of 10 · 186 trades